Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Interest Income

Interest Income at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$8.91M-29.3%

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's interest income?
NewAmsterdam Pharma Company (NAMS) reported interest income of $5.65M in Q1 2026.
How has NewAmsterdam Pharma Company's interest income changed year-over-year?
NewAmsterdam Pharma Company's interest income decreased by 23.1% year-over-year, from $7.35M to $5.65M.
What is the long-term trend for NewAmsterdam Pharma Company's interest income?
Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's interest income has grown at a 56.4% compound annual growth rate (CAGR), from $11.28M to $27.59M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.